Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Henan Genuine Biotech Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, BERRY, LAYLA D. The prosecution is situated within 1 distinct art unit, reflecting a focused technical review for this pharmaceutical filing.
BERRY, LAYLA D is the busiest examiner for the company, currently managing the 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the company's current patent office activity is concentrated. This 1 pending office action represents the entirety of the company's active docket in the Biotechnology & Pharmaceuticals sector.
The use of 1 distinct art unit indicates that the subject matter of the 1 pending office action falls within a specific biological specialty. Practitioners can focus their efforts on the examination style of BERRY, LAYLA D. With 1 pending office action, the portfolio's immediate administrative needs are centered within the 1 distinct art unit and the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18205628 | IMMUNOMODULATOR COMPOSITION COMPRISING AZVUDINE | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726801 | CRYSTAL OF 4’-SUBSTITUTED NUCLEOSIDE, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING THE SAME, AND USE THEREOF | BERRY, LAYLA D | 1693 | §112 | Non-Final OA | — | Pending | Jul 04, 2024 |
| 18205628 | IMMUNOMODULATOR COMPOSITION COMPRISING AZVUDINE | DAHLIN, HEATHER RAQUEL | 1629 | §103 | Final Rejection | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHenan Genuine Biotech Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Layla D Berry has the most, with 1 of Henan Genuine Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
